BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 38646651)

  • 21. Expanding the Potential of Neoantigen Vaccines: Harnessing Bacille Calmette-Guérin Cell-Wall-Based Nanoscale Adjuvants for Enhanced Cancer Immunotherapy.
    Liu K; Peng J; Guo Y; Li Y; Qi X; Duan D; Li T; Li J; Niu Y; Han G; Zhao Y
    ACS Nano; 2024 May; 18(18):11910-11920. PubMed ID: 38680054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy.
    Liang Z; Cui X; Yang L; Hu Q; Li D; Zhang X; Han L; Shi S; Shen Y; Zhao W; Ju Q; Deng X; Wu Y; Sheng W
    Int J Pharm; 2021 Oct; 608():121091. PubMed ID: 34555477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma.
    Chu Y; Qian L; Ke Y; Feng X; Chen X; Liu F; Yu L; Zhang L; Tao Y; Xu R; Wei J; Liu B; Liu Q
    J Nanobiotechnology; 2022 Apr; 20(1):190. PubMed ID: 35418151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carrier-Free Nanovaccine: An Innovative Strategy for Ultrahigh Melanoma Neoantigen Loading.
    Zeng T; Zang W; Xiao H; Jiang Y; Lin S; Wang M; Li S; Li L; Li C; Lu C; Yang H
    ACS Nano; 2023 Sep; 17(18):18114-18127. PubMed ID: 37695697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoimmunity in immune checkpoint inhibitor-induced immune-related adverse events: A focus on autoimmune skin toxicity and pneumonitis.
    Berner F; Flatz L
    Immunol Rev; 2023 Sep; 318(1):37-50. PubMed ID: 37548043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An engineered influenza virus to deliver antigens for lung cancer vaccination.
    Ji D; Zhang Y; Sun J; Zhang B; Ma W; Cheng B; Wang X; Li Y; Mu Y; Xu H; Wang Q; Zhang C; Xiao S; Zhang L; Zhou D
    Nat Biotechnol; 2024 Mar; 42(3):518-528. PubMed ID: 37231262
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
    Rojas LA; Sethna Z; Soares KC; Olcese C; Pang N; Patterson E; Lihm J; Ceglia N; Guasp P; Chu A; Yu R; Chandra AK; Waters T; Ruan J; Amisaki M; Zebboudj A; Odgerel Z; Payne G; Derhovanessian E; Müller F; Rhee I; Yadav M; Dobrin A; Sadelain M; Łuksza M; Cohen N; Tang L; Basturk O; Gönen M; Katz S; Do RK; Epstein AS; Momtaz P; Park W; Sugarman R; Varghese AM; Won E; Desai A; Wei AC; D'Angelica MI; Kingham TP; Mellman I; Merghoub T; Wolchok JD; Sahin U; Türeci Ö; Greenbaum BD; Jarnagin WR; Drebin J; O'Reilly EM; Balachandran VP
    Nature; 2023 Jun; 618(7963):144-150. PubMed ID: 37165196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vaccine-like nanomedicine for cancer immunotherapy.
    Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
    J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anion-Coordination-Driven Assembly.
    Liang L; Zhao W; Yang XJ; Wu B
    Acc Chem Res; 2022 Nov; 55(22):3218-3229. PubMed ID: 36331808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity.
    Liu L; Chen J; Zhang H; Ye J; Moore C; Lu C; Fang Y; Fu YX; Li B
    Nat Cancer; 2022 Apr; 3(4):437-452. PubMed ID: 35393580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two-Pronged Intracellular Co-Delivery of Antigen and Adjuvant for Synergistic Cancer Immunotherapy.
    Meng J; Zhang P; Chen Q; Wang Z; Gu Y; Ma J; Li W; Yang C; Qiao Y; Hou Y; Jing L; Wang Y; Gu Z; Zhu L; Xu H; Lu X; Gao M
    Adv Mater; 2022 May; 34(21):e2202168. PubMed ID: 35362203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Symphony of nanomaterials and immunotherapy based on the cancer-immunity cycle.
    Li Q; Shi Z; Zhang F; Zeng W; Zhu D; Mei L
    Acta Pharm Sin B; 2022 Jan; 12(1):107-134. PubMed ID: 35127375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trp2 Peptide-Assembled Nanoparticles with Intrinsically Self-Chelating
    He Z; Jia H; Zheng M; Wang H; Yang W; Gao L; Zhang Z; Xue J; Xu B; Yang W; Xing G; Gao X; Gao F
    ACS Appl Bio Mater; 2021 Jul; 4(7):5707-5716. PubMed ID: 35006752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metal-Coordinated Supramolecular Self-Assemblies for Cancer Theranostics.
    Xu J; Wang J; Ye J; Jiao J; Liu Z; Zhao C; Li B; Fu Y
    Adv Sci (Weinh); 2021 Aug; 8(16):e2101101. PubMed ID: 34145984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines.
    Blass E; Ott PA
    Nat Rev Clin Oncol; 2021 Apr; 18(4):215-229. PubMed ID: 33473220
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy.
    Xu J; Lv J; Zhuang Q; Yang Z; Cao Z; Xu L; Pei P; Wang C; Wu H; Dong Z; Chao Y; Wang C; Yang K; Peng R; Cheng Y; Liu Z
    Nat Nanotechnol; 2020 Dec; 15(12):1043-1052. PubMed ID: 33139933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
    Ott PA; Hu-Lieskovan S; Chmielowski B; Govindan R; Naing A; Bhardwaj N; Margolin K; Awad MM; Hellmann MD; Lin JJ; Friedlander T; Bushway ME; Balogh KN; Sciuto TE; Kohler V; Turnbull SJ; Besada R; Curran RR; Trapp B; Scherer J; Poran A; Harjanto D; Barthelme D; Ting YS; Dong JZ; Ware Y; Huang Y; Huang Z; Wanamaker A; Cleary LD; Moles MA; Manson K; Greshock J; Khondker ZS; Fritsch E; Rooney MS; DeMario M; Gaynor RB; Srinivasan L
    Cell; 2020 Oct; 183(2):347-362.e24. PubMed ID: 33064988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
    Aikins ME; Xu C; Moon JJ
    Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer.
    Ni Q; Zhang F; Liu Y; Wang Z; Yu G; Liang B; Niu G; Su T; Zhu G; Lu G; Zhang L; Chen X
    Sci Adv; 2020 Mar; 6(12):eaaw6071. PubMed ID: 32206706
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
    Martin JD; Cabral H; Stylianopoulos T; Jain RK
    Nat Rev Clin Oncol; 2020 Apr; 17(4):251-266. PubMed ID: 32034288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.